To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma
1. The patient or their legal guardian understands and voluntarily signs the informed consent form and is expected to complete the follow-up examinations and treatments.
Alanine transaminase (ALT) ≤3 times the upper limit of normal (ULN);
Aspartate transaminase (AST) ≤3 times ULN;
Total bilirubin ≤1.5 times ULN;
1. Diagnosed with or treated for invasive malignant tumors other than multiple myeloma.
Single group
infusion of GPRC5D-CD19 CAR T injection
Biological/VaccineInfusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Objective Response Rate
Subjects were evaluated for efficacy according to the IMWG Efficacy Assessment Criteria (2016 revision).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
